Companies
Enviva
expanding massive pellet production facilities despite recent financial restructuring.
- Country
- United States
- Ticker
- EVA
wood-pellets
us
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| biofuels-bioenergy | ✓ | ✓ | ✓ | ✓ |
Regulatorsepafercademe
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $250 million in new money financing provided by stakeholders through an Equity Rights Offering at emergence from Chapter 11 bankruptcy in December 2024 | ir.envivabiomass.com · businesswire.com |
| Capacity | Approximately 6.2 million metric tons per year from ten operating plants, with an additional 1 million metric tons per year expected from the new Epes, Alabama plant once fully ramped | ir.envivabiomass.com · businesswire.com · envivabiomass.com · sec.gov |
| Certification | Certified to Sustainable Biomass Program (SBP), Forest Stewardship Council (FSC), Program for the Endorsement of Forest Certification (PEFC), and Sustainable Forestry Initiative (SFI) standards | envivabiomass.com |
| Regulatory approval | Construction permits received from Alabama Department of Environmental Management for the Epes facility and Mississippi Department of Environmental Quality for the Bond facility | envivabiomass.com |
| Production site | Ten operating plants in Virginia, North Carolina, South Carolina, Georgia, Florida, and Mississippi; one plant under construction in Epes, Alabama | ir.envivabiomass.com · sec.gov |
| Headcount | 1,200+ associates | envivabiomass.com |
| Revenue | Revenue experienced a significant decline during 2023, with losses totaling hundreds of millions medium confidence | news.mongabay.com |
Independent sources: businesswire.com · news.mongabay.com · sec.gov
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biomass for energy | biofuels-bioenergy | High | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.